Cidara's Narrow Spread: The Bidding War Is Over (NASDAQ:CDTX)

Core Insights - Cidara Therapeutics, Inc. (CDTX) experienced a significant pre-market trading surge, reaching approximately $200, which represents a 90% increase compared to the previous day's closing price due to a report by the Financial Times regarding a potential collaboration with Merck & Co., Inc. [1] Company Summary - Cidara Therapeutics, Inc. is currently in the spotlight following a report that has led to a substantial increase in its stock price, indicating strong market interest and potential investor optimism [1]. Market Reaction - The pre-market trading activity reflects a notable investor response, suggesting that the news regarding Cidara and Merck has created a favorable outlook for the company's future performance [1].